Kjellström T, Blychert E, Lindgärde F
Department of Medicine, University of Lund, Malmö General Hospital, Sweden.
J Intern Med. 1994 Jul;236(1):51-6. doi: 10.1111/j.1365-2796.1994.tb01119.x.
To study the effects on blood pressure and glucose homeostasis of felodipine, a calcium antagonist.
A double-blind randomized cross-over study comparing felodipine ER and placebo.
A university centre of diabetic care in Malmö, Sweden.
Seventeen hypertensive type II diabetic males on oral sulfonylurea (glibenclamide) treatment.
Four-week treatment periods separated by a 2-week wash-out period. Felodipine 10-20 mg once daily was given.
Blood pressure, heart rate, HbA1c and response to oral glucose tolerance test; glucose, insulin and c-peptide. Measured before randomization and at the end of each double-blind treatment period.
Blood pressure was significantly reduced during felodipine treatment and heart rate slightly increased. Felodipine did not influence insulin or c-peptide levels. There was no significant change in glucose levels but an increase in HbA1c.
The study demonstrated that felodipine is an effective agent for type II diabetic patients on glibenclamide treatment. The effect on HbA1c is noteworthy even if not of clinical significance in the short term. Controlled long-term studies in diabetic patients are needed to fully evaluate antihypertensive agents.
研究钙拮抗剂非洛地平对血压及葡萄糖稳态的影响。
一项比较非洛地平缓释片与安慰剂的双盲随机交叉研究。
瑞典马尔默的一个大学糖尿病护理中心。
17名接受口服磺脲类药物（格列本脲）治疗的II型糖尿病男性高血压患者。
为期4周的治疗期，中间间隔2周的洗脱期。给予非洛地平每日一次，剂量为10 - 20毫克。
血压、心率、糖化血红蛋白以及口服葡萄糖耐量试验的反应；血糖、胰岛素和C肽。在随机分组前以及每个双盲治疗期结束时进行测量。
非洛地平治疗期间血压显著降低，心率略有升高。非洛地平不影响胰岛素或C肽水平。血糖水平无显著变化，但糖化血红蛋白有所升高。
该研究表明，非洛地平对接受格列本脲治疗的II型糖尿病患者是一种有效的药物。即使短期内对糖化血红蛋白的影响无临床意义，但其作用仍值得关注。需要对糖尿病患者进行长期对照研究以全面评估抗高血压药物。
